estrogen

Ethisterone (17α-Ethynyltestosterone) is a progestogen hormone.

Tamoxifen Citrate is an orally active selective estrogen receptor modulator (SERM) that blocks estrogen activity in breast cells while activating estrogen signaling in cells such as those of the bone, liver, and uterus. As an Hsp90 activator, it enhances the ATPase activity of the Hsp90 chaperone complex, induces autophagy and apoptosis, and can be used to generate gene knockout models in CreER(T2) transgenic mice as well as liver injury models.

Estradiol (E2) is a naturally occurring steroidal sex hormone that is essential for female fertility and maintenance of secondary sexual characteristics. Estradiol upregulates IL-6 expression through estrogen receptor beta (ERβ).

Letrozole (CGS 20267) is an Aromatase Inhibitor. The mechanism of action of letrozole is as an Aromatase Inhibitor.

Bazedoxifene acetate (WAY-TES 424) is a novel selective estrogen receptor modulator (SERM).

Etonogestrel (Implanon) is a steroidal progestin used as hormonal contraceptives.

Estrone sulfate sodium (17β-Estrone 3-sulfate) is an endogenous steroid and an estrogen ester that is biologically inactive. It is converted by steroid sulfatase into estrone . Estrone sulfate sodium has been investigated as a ligand for targeting organic anion transporting polypeptides f

Bazedoxifene hydrochloride (TSE 424 hydrochloride) is an orally active, selective, and potent estrogen receptor modulator (SERM) that crosses the blood-brain barrier and is an inhibitor of IL-6/GP130 protein interactions with high affinity for ERα and ERβ. It has a high affinity for ERα and ERβ and can be used to study postmenopausal osteoporosis and vasodilator-related diseases.

Fadrozole hydrochloride (CGS 16949A) is a model aromatase inhibitor that effectively suppresses estrogen production in fish ovaries.

DPN (Diarylpropionitrile) is an selective agonist of estrogen receptor β (ERβ) .

FLTX1 is a fluorescent derivative of Tamoxifen, designed to efficiently target and label intracellular Tamoxifen-binding sites (estrogen receptors) both under permeabilized and non-permeabilized conditions. Additionally, FLTX1 demonstrates strong antiestrogenic activity in breast cancer cells, resembling the potent antiestrogenic properties of Tamoxifen. Notably, FLTX1 does not exhibit any estrogenic agonistic effect on the uterus.

Estrogen receptor antagonist 8 acts as an estrogen receptor (ER) antagonist with anti-uterine activity and potential anti-tumorigenic activity and can be used to study ovarian dysfunction.

Estrogen receptor-agonist-1 (compound 4e) is an estrogen receptor (ER) agonist that binds to ERα with high affinity.

Estrogen receptor modulator11 (Compound 27) is a tetrahydroisoquinoline derivative. It exhibits affinity for the estrogen receptor (ER), with IC50 values of 285 nM for ERα and 421 nM for ERβ. Estrogen receptor modulator11 does not demonstrate antagonist activity in MCF-7 cell assays.

Estrogen receptor modulator13 (Compound 5D) is an estrogen receptor antagonist with significant cytotoxic effects on MCF7 cells, exhibiting an IC50 value of 8.50 μM. Estrogen receptor modulator13 holds potential for breast cancer research.

Estrogen receptor modulator 6 (compound 3a) is a highly specific and potent agonist of the estrogen receptor (ER) β, exhibiting remarkable affinity (K i = 0.44 nM) and impressive 19-fold selectivity for ERβ over ERα, as evidenced by its affinity (K i = 8.4 nM).

Estrogen receptor-IN-1 (compound 16) is an effective estrogen receptor (ER) inhibitor with IC50 values of 13 μM for ERα and 5 μM for ERβ, respectively [1].

Estrogen Receptor Antagonist 7 (Compound 13) is a potent antagonist of estrogen receptors (ER), demonstrating antiproliferative effects against breast and ovarian cancer cells, along with anticancer and anti-uterotrophic activities [1].

Estrogen receptor β antagonist 2 is a selective and potent estrogen receptor β (ERβ) antagonist, with an IC50 of 109.10 μM for ERα and 0.63 μM for ERβ.

Estrogen receptor α antagonist 1 (compound 35) is a highly selective antagonist of estrogen receptor α, demonstrating an IC50 of 0.02 μM against this receptor and also affecting estrogen receptor β. This compound is utilized in tumor research.

Estrogen receptor antagonist 5 is a potent inhibitor of the Estrogen receptor, a ligand-activated transcriptional regulatory protein that interacts with endogenous estrogens and mediates various biological effects. [Estrogen receptor antagonist 5] shows promise for studies on metastatic disease.

Estrogen receptor antagonist 6, also known as Compound 166, is a potent antagonist of the ligand-activated transcriptional regulatory protein Estrogen receptor, which interacts with endogenous estrogens to mediate various biological effects.

Estrogen Receptor Antagonist 4 is a potent inhibitor of the estrogen receptor (ER), crucial for regulating cell growth, differentiation, and apoptosis. This compound holds promise for cancer research[1].

Estrogen receptor antagonist 2 is a selective down-regulator of the estrogen receptor, with research potential for breast cancer disease. Estrogen (E2) and estrogen alpha receptor (ERα) are important drivers of breast cancer development.